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SUMMARY
Background
Preliminary data suggest that performance of non-invasive markers for liver ﬁbrosis in
hepatitis C may improve when combined. Three algorithms based on the combination
of Fibrotest, Forns’ index and AST-to-platelet ratio (APRI) have been proposed:
Sequential Algorithm for Fibrosis Evaluation (SAFE biopsy); Fibropaca algorithm; Leroy
algorithm.
Aim
To compare three algorithms to diagnose signiﬁcant ﬁbrosis (‡F2 by METAVIR) and
cirrhosis (F4).
Methods
A total of 1013 HCV monoinfected cases undergoing liver biopsy were consecutively
enrolled in seven centres. Fibrotest, APRI and Forns’ index were measured at the time
of liver biopsy, considered the reference standard.
Results
Overall, performance of combination algorithms was signiﬁcantly higher than the single
non-invasive methods (P < 0.0001). SAFE biopsy and Fibropaca algorithm saved a sig-
niﬁcantly higher number of liver biopsies than the single methods (P < 0.0001). For
‡F2, Fibropaca algorithm saved more biopsies than SAFE biopsy (51.7% vs. 43.8%,
P = 0.0003), but with lower accuracy (87.6% vs. 90.3%, P = 0.05). Regarding F4, the
number of saved liver biopsies did not differ between SAFE biopsy and Fibropaca algo-
rithm (79.1% vs. 76.2%, P = 0.12). However, SAFE biopsy showed a lower accuracy
when compared with Fibropaca algorithm (91.2% vs. 94%, P = 0.02). As to Leroy algo-
rithm, although it showed a good performance for ‡F2 (93.5% accuracy), it saved less
liver biopsies than SAFE biopsy and Fibropaca algorithm (29.2% vs. 43.8% and 51.7%
respectively, P < 0.0001).
Conclusions
SAFE biopsy and the Fibropaca algorithm have excellent performance for liver ﬁbrosis
in hepatitis C, allowing a signiﬁcant reduction in the need for liver biopsies. They can
be useful in clinical practice and for large-scale screening.
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INTRODUCTION
Liver ﬁbrosis is the hallmark of disease progression in
chronic hepatitis C (CHC).1 The precise stage of hepatic
ﬁbrosis is the most important predictor of disease pro-
gression and determines the need for antiviral therapy.2
Liver biopsy is still considered the standard of reference
to stage liver ﬁbrosis in CHC.2, 3 However, the accuracy
of liver biopsy depends on the quality of liver specimen,
the experience of liver pathologist and the histological
staging system adopted.4–7 In addition, liver biopsy is
invasive, costly and currently disliked by many patients
and by several physicians.8–10 Its universal use in CHC is
unpractical due to the huge number of chronically
infected and often asymptomatic carriers.2, 11
These limitations have stimulated the search for non-
invasive tools to diagnose and stage liver ﬁbrosis.12, 13 A
variety of methods have been proposed, including simple
markers based on routine laboratory tests, such as the
AST-to-platelet ratio index (APRI) and Forns’ index, and
more complex scores such as Fibrotest.14–16 These three
serum non-invasive markers are currently among the
most validated.17–20
Recently, we and others have reported that combina-
tions of these serum non-invasive markers for liver ﬁbro-
sis may represent a rational approach to further improve
the diagnostic accuracy of the single markers and to
markedly reduce, rather than completely abolish, the
need for liver biopsy.17, 21–24 Importantly, recent guide-
lines from the Asian Paciﬁc Association for the Study of
the Liver about liver ﬁbrosis management concluded that
a stepwise algorithm incorporating non-invasive markers
of ﬁbrosis may reduce the number of liver biopsies by
about 30%.25
The Sequential Algorithms for Fibrosis Evaluation
(SAFE biopsy) combines sequentially APRI and Fibrotest;
Fibropaca algorithm is a synchronous combination of
Fibrotest, APRI and Forns’ Index; Leroy algorithm is a
synchronous combination of Fibrotest and APRI. In the
original reports, these algorithms could avoid 30–80% of
liver biopsies with high diagnostic accuracy.22, 23, 26
We here describe the results of an international, mul-
ticentre study aiming a large-scale, direct comparison of
these three combination algorithms for identiﬁcation of
liver ﬁbrosis in CHC. Our results show that, among
these three combination algorithms, SAFE biopsy and
Fibropaca algorithm may save up to 79% liver biopsies
and preserve an excellent accuracy. These combination
algorithms may signiﬁcantly reduce the screening costs
related to the staging of liver ﬁbrosis in patients with
CHC.
METHODS
Objectives
The aim of this study was to compare three recently
described algorithms that combine serum non-invasive
markers (APRI, Fibrotest, Forns’ index) to detect signiﬁ-
cant ﬁbrosis (‡F2 according to METAVIR classiﬁcation)
and cirrhosis (F4) in patients with CHC. These thresh-
olds were selected as the ﬁrst is generally considered an
indication for antiviral therapy and the second requires
a speciﬁc management and follow-up including
screening for hepatocellular carcinoma and oesophageal
varices.2
Participants
This was an international, multicentre retrospective study
of patients with CHC seen between January 2005 and
January 2008 in seven clinical centres across Europe. Of
1215 consecutive untreated patients with CHC who had
a liver biopsy and serum non-invasive markers for liver
ﬁbrosis performed on the same day, we included 1013
patients mono-infected with HCV. All patients were
positive for serum HCV-RNA by polymerase chain reac-
tion (Amplicor HCV Monitor test; Roche Diagnostics,
Indianapolis, IN, USA) and had well-compensated
chronic HCV infection, all cirrhotic cases being in
Child–Pugh class A. Information on patients’ demo-
graphics [gender, age, body mass index (BMI)], HCV
genotype, liver biopsy characteristics (length and number
of portal tracts) had been recorded in each Centre on
the day of biopsy. The exclusion criteria were coinfection
with HBV (56) or HIV (53) and co-morbidities that
could confound the results of the non-invasive markers
adopted, including current alcohol intake (>20 g ⁄day),
haemolysis, Gilbert’s syndrome and autoimmune throm-
bocytopenia (93 cases).
Histological assessment
Liver biopsies were analysed in each centre by the local
pathologist and stage of ﬁbrosis was reported according
to the METAVIR classiﬁcation.27 Signiﬁcant ﬁbrosis was
deﬁned as a METAVIR score ‡F2, while cirrhosis was
deﬁned as F4. To assess if and how the characteristics of
liver specimens affect concordance between combination
algorithms of non-invasive serum markers and liver
biopsy, a subgroup analysis was performed according to
the following criteria: liver biopsies longer than 2 cm
and containing more than 11 complete portal tracts
were considered as the ‘gold’ standard, as recently
recommended.2
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Non-invasive markers of liver fibrosis
The parameters [aspartate aminotransferase (AST), c-
glutamyl-transpeptidase (cGT), total bilirubin, a2-macro-
globulin, apolipoprotein A1, haptoglobin, platelet count,
cholesterol] allowing for calculation of Fibrotest, APRI
and Forns’ index were determined on blood sampled the
day of liver biopsy. APRI was calculated by dividing the
AST level (IU ⁄L), expressed as the number of times
above the upper limit of normal (ULN), by platelet count
(109 ⁄L): AST ( ⁄ULN) · 100 ⁄platelet count (109 ⁄L).14
Forns’ index was calculated by applying the following
regression equation: 7.811 ) 3.131 ln (platelet count
(109 ⁄L)) + 0.781 ln (cGT (IU ⁄L)) + 3.467 ln (age
(y)) ) 0.014 (cholesterol (mg ⁄dL)).15
Fibrotest is a non-invasive blood test that combines
ﬁve serum biochemical markers (a2-macroglobulin, hap-
toglobin, cGT, total bilirubin, apolipoprotein A1) with
patient age and gender in a patented artiﬁcial intelligence
algorithm to generate a measure of ﬁbrosis in the liver.16
Fibrotest values were obtained through Biopredictive
(Fibrotest; Biopredictive, Paris, France).
Algorithms combining serum non-invasive markers for
liver fibrosis
Three recently described combination algorithms of
serum markers were applied to the 1013 patients and the
results were compared with liver histology, considered
the standard of reference. For the purpose of this study,
the coordinating Centre (VIMM-Padova) received the
results of APRI, Forns’ index and Fibrotest blinded to
any information about liver histology. One member of
the coordinating centre (GS) applied the three algorithms
and sent back the results to the different centres. Only at
this point, the participating centres communicated the
results of liver biopsy to the coordinating Centre.
SAFE biopsy
Two distinct algorithms for the detection of signiﬁcant
ﬁbrosis and of cirrhosis based on sequential use of APRI,
Fibrotest and liver biopsy were applied to the 1013
patients. The two algorithms use APRI as initial screen-
ing test, followed by Fibrotest as second step and limit
the use of liver biopsy to those patients in whom the
non-invasive markers have inadequate accuracy
(Figures 1 and 2).26
Fibropaca algorithm
An algorithm for detection of signiﬁcant ﬁbrosis and cir-
rhosis based on the synchronous use of APRI, Forns’
index, Fibrotest and liver biopsy was applied to the 1013
patients. The algorithm is based on the concordance
between Fibrotest and APRI and ⁄or Forns’ index, and it
limits the use of liver biopsy to discordant cases
(Figures 3 and 4).22
Leroy algorithm
An algorithm for detection of signiﬁcant ﬁbrosis based
on the synchronous use of APRI, Fibrotest and liver
biopsy was applied to the 1013 patients. The algorithm is
based on the concordance between APRI and Fibrotest,
and limits the use of liver biopsy to those cases with
intermediate values of serum markers, which present
with inadequate accuracy (Figure 5).23
Ethics
Written informed consent was obtained from all patients
at the time of liver biopsy and the study was conducted
according to the Declaration of Helsinki. The Ethics
Committee for the Clinical Experimentation of the
HCV patients
(n = 1013)
(n = 1013)
(n = 422) (n = 438)
(n = 438)
(n = 291)
Liver biopsy needed Significant fibrosis present
No need for liver biopsy
(n = 147)
(n = 569)
(n = 444)
(n = 153)
Fibrotest
≤0.5
≤0.48
0.5–1.5 >1.5
>0.49
APRI
Figure 1 | SAFE biopsy for significant fibrosis (‡F2 by
METAVIR). The figure reports the cut-off used for APRI
and Fibrotest in the decisional tree and the distribution
of patients in the different directions when the algo-
rithm was applied to the 1013 HCV patients of this
study. SAFE, sequential algorithm for fibrosis evaluation;
APRI, AST-to-platelet ratio index; HCV, hepatitis C
virus.
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Province of Padova speciﬁcally exempted the study from
ethic approval. Indeed, all the data collected for this study
were part of a series of examinations, which are routinely
performed in patients with CHC (blood exam and liver
biopsy) and no additional procedure was required.
Discordance determination
Discordance was highly attributable to biopsy failure if
the biopsy was of poor quality (size <1 cm). Discordance
was considered highly attributable to Fibrotest, APRI or
Forns’ score failure if liver biopsy was longer than 2 cm
and contained more than 11 complete portal tracts. Dis-
cordance was considered undetermined if liver biopsy
length was ranging between 1 and 2 cm. We considered
that patients with F4 stage on Fibrotest, APRI or liver
biopsy had cirrhosis if they exhibited at least two addi-
tional criteria of cirrhosis among radiological (liver mor-
phology abnormalities at ultrasound), endoscopic (signs
of portal hypertension) or biological criteria [low blood
platelets (<150 g ⁄L) or low PT ratio (<80%)].22
Statistical analysis
Descriptive results were expressed as mean  SD (stan-
dard deviation) or number (percentage) of patients with
a condition. The t-test or nonparametric Mann–Whitney
test was used to compare quantitative data and the Chi-
squared test was applied for comparison of frequency
data. All tests were two-tailed and P-values < 0.05 were
considered signiﬁcant. The performance of the algo-
rithms combining non-invasive markers for liver ﬁbrosis
was measured as sensitivity, speciﬁcity, positive predictive
value (PPV), negative predictive value (NPV), accuracy,
positive and negative likelihood ratio (LR). Sensitivity,
speciﬁcity, PPV, NPV and accuracy were expressed as
percentage. For the aim of this study, predictive values
were considered clinically reliable for avoiding liver
HCV patients
(n = 1013)
(n = 1013)
(n = 524)
Yes No
Significant fibrosis present/
absent – No need for liver
biopsy
Fibrotest + APRI and/or FORNS
Concordance for significant fibrosis
Liver biopsy needed
(n = 489)
Figure 3 | Fibropaca algorithm for significant fibrosis
(‡F2 by METAVIR). The figure reports the decisional
tree of the algorithm, based on the concordance of
Fibrotest, APRI and Forns’ index, and the distribution of
patients in the different directions when the algorithm
was applied to the 1013 HCV patients of this study. The
following cut-off values were used to define concor-
dance between the serum non-invasive markers:
Fibrotest <0.49 (no significant fibrosis), Fibro-
test ‡ 0.49 (significant fibrosis); APRI £ 0.5 (no signifi-
cant fibrosis), APRI >1.5 (significant fibrosis); Forns’
index <4.2 (no significant fibrosis), Forns’ index >6.9
(significant fibrosis). APRI, AST-to-platelet ratio index;
HCV, hepatitis C virus.
HCV patients
(n = 1013)
(n = 1013)
APRI
(n = 430) (n = 485)
≤1 1–2
(n = 98)
>2
(n = 583)
Fibrotest
(n = 212) (n = 197)(n = 174)
≤0.48 ≥0.750.49–0.75
Liver biopsy needed
(n = 212)
Cirrhosis absent
No need for liver biopsy
(n = 604)
Cirrhosis present
No need for liver biopsy
(n = 197)
Figure 2 | SAFE biopsy for cirrhosis (F4 by METAVIR).
The figure reports the cut-off used for APRI and Fibro-
test in the decisional tree and the distribution of
patients in the different directions when the algorithm
was applied to the 1013 HCV patients of this study.
SAFE, sequential algorithm for fibrosis evaluation; APRI,
AST-to-platelet ratio index; HCV, hepatitis C virus.
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biopsy when they were >85%. The use of this cut-off as
a clinical decision point is consistent with several publi-
cations in the ﬁeld.14, 26, 28–30 The diagnostic value of
the non-invasive methods was expressed using the area
under the receiver operating characteristic curve (AU-
ROC) and its corresponding 95% conﬁdence intervals
(CI). AUROCs were calculated including non-invasive
markers quantitative values using empirical nonparamet-
ric method according to DeLong et al. and compared
using the method of Hanley et al.31, 32
Standardisation of AUROCs according to the
prevalence of fibrosis stages
As recently proposed by Poynard et al., to prevent spec-
trum biases, AUROCs were adjusted according to the
prevalence of ﬁbrosis stages using the Difference between
advanced and non-advanced ﬁbrosis (DANA) index.33
This DANA is an index for standardising comparisons
to transform any different prevalence proﬁle into a
homogeneous distribution of ﬁbrosis stages from F0 to
F4, as deﬁned by a prevalence of 0.20 for each of the ﬁve
METAVIR stages (standard prevalence). DANA was
calculated according to the following formula: [(preva-
lence F2 · 2 + prevalence F3 · 3 + prevalence F4 ·
4) ⁄ (prevalence F2 + prevalence F3 + prevalence F4)] )
[prevalence F1 ⁄ (prevalence F0 + prevalence F1)]. The
adjusted AUROCs (adjAUROCs) were calculated as fol-
lows: AdjAUROC = observed AUROC (obAUROC) +
(0.1056) · (2.5 ) DANA).
RESULTS
Characteristics of the 1013 HCV patients
The main demographic, laboratory and histological fea-
tures of the 1013 patients with CHC are summarised in
Table 1. Overall, there were 574 (56.7%) men and 439
(43.3%) women with mean age of 48.0  12.0 years. All
patients were treatment-naı¨ve. Signiﬁcant ﬁbrosis was
present in 552 (54.5%) patients, while cirrhosis was pres-
ent in 113 (11.2%). The mean length of liver specimen
was 20.0  8.2 mm and the mean number of portal
tracts was 11.0  6.0. Biopsy length was greater than
20 mm (‘gold’ standard) in 459 (45.3%) cases.
HCV patients
(n = 1013)
(n = 1013)
(n = 1013)(n = 1013)(n = 1013)
(n = 126) (n = 170)
Fibrotest + APRI
Fibrotest < 0.22 Fibrotest > 0.59Intermediate
valuesAPRI < 0.5 APRI > 2
Significant fibrosis Significant fibrosis
absent present
No need for liver No need for liver
biopsy biopsy
needed
(n = 717)
Liver
biopsy
Figure 5 | Leroy algorithm for significant fibrosis (‡F2
by METAVIR). The figure reports the cut-off used for Fi-
brotest and APRI in the decisional tree and also the dis-
tribution of patients in the different directions when the
algorithm was applied to the 1013 HCV patients of this
study. APRI, AST-to-platelet ratio index; HCV, hepatitis
C virus.
HCV patients
(n = 1013)
(n = 1013)
Fibrotest + APRI
Concordance for cirrhosis
Yes No
(n = 772)
Cirrhosis present/absent
No need for liver biopsy
Liver biopsy needed
(n = 241)
Figure 4 | Fibropaca algorithm for cirrhosis (F4 by
METAVIR). The figure reports the decisional tree of the
algorithm, based on the concordance of Fibrotest and
APRI and the distribution of patients in the different
directions when the algorithm was applied to the 1013
HCV patients of this study. The following cut-off values
were used to define concordance between the serum
non-invasive markers: Fibrotest <0.75 (no cirrhosis), Fi-
brotest ‡ 0.75 (cirrhosis); APRI £ 1 (no cirrhosis), APRI
>2 (cirrhosis). APRI, AST-to-platelet ratio index; HCV,
hepatitis C virus.
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Fibrotest, APRI and Forns’ index for diagnosis of
significant fibrosis
The performance of Fibrotest, APRI and Forns’ index to
diagnose signiﬁcant ﬁbrosis is shown in Table S1.
Fibrotest showed a good PPV (85.7%) to rule-in signiﬁ-
cant ﬁbrosis, with an overall AdjAUROC of 0.77. Based
on the high PPV value, liver biopsy could have been
avoided in 350 (34.6%) of cases. For the diagnosis of sig-
niﬁcant ﬁbrosis, APRI showed an overall AdjAUROC of
0.76. The cut-off to rule-out signiﬁcant ﬁbrosis (0.5)
showed a only discrete NPV (76.7%), while the cut-off to
rule-in signiﬁcant ﬁbrosis had a very good PPV (89.9%).
Moreover, 448 (44.2%) cases fall in between 0.5 and 1.5
cut-offs and could not be classiﬁed. Based on the high
PPV value of the 1.5 cut-off and considering the rela-
tively low NPV of the 0.5 cut-off and the unclassiﬁed
cases, liver biopsy could have been avoided in 158
(15.6%) patients. For the diagnosis of signiﬁcant ﬁbrosis,
Forns’ index showed an overall AdjAUROC of 0.70. The
cut-off to rule-out signiﬁcant ﬁbrosis (4.2) showed a only
discrete NPV (73.7%), and the cut-off to rule-in signiﬁ-
cant ﬁbrosis had a poor PPV (68.9%). Moreover, 398
(39.3%) cases fall in between 4.2 and 6.9 cut-offs and
could not be classiﬁed. Based on the unsatisfactory PPV
and NPV values of Forns’ index in our population, we
could not use any cut-off to reliably rule-in or rule-out
signiﬁcant ﬁbrosis. Approximately 15% of patients were
infected by HCV-3 and showed signiﬁcantly lower cho-
lesterol levels as compared with cases infected with HCV
non-3 (2.1  1.2 vs. 2.54  1.4 mmol ⁄L, P < 0.01).
Although it has been suggested that performance of
Forns’ index might be lower in HCV-3 cases,34 in our
series, the ObAUROC of Forns’ index was similar in
HCV-3 and non-3 cases (0.63 vs. 0.64), and this is con-
sistent with previous observations.21
Fibrotest and APRI for diagnosis of cirrhosis
The performance of Fibrotest and APRI to diagnose cir-
rhosis is shown in Table S2. Fibrotest showed an excellent
NPV (90.8%) to rule-out cirrhosis, with an overall AdjAU-
ROC of 0.78. Based on the high NPV value, liver biopsy
could have been avoided in 670 (68.1%) cases. With regard
to APRI, the cut-off to rule-out cirrhosis (1) showed an
excellent NPV (96.1%) and the cut-off value to rule-in cir-
rhosis (2) showed a poor PPV (55.2%), with an overall
AdjAUROC of 0.83. Moreover, 165 (16.3%) cases fall in
between 1 and 2 cut-offs and could not be classiﬁed. Based
on the high NPV value of 1 cut-off and considering the
low PPV of 2 cut-off and the unclassiﬁed cases, liver
biopsy could have been avoided in 580 (57.3%) patients.
Combination algorithms for diagnosis of significant
fibrosis
The performance of the three algorithms to diagnose sig-
niﬁcant ﬁbrosis is described in Table 2. Figures 1, 3 and
5 describe the three algorithms for signiﬁcant ﬁbrosis,
including related decisional tree and distribution of the
study population.
SAFE biopsy showed a signiﬁcantly higher accuracy
than the single non-invasive markers (P < 0.0001). More-
over, it saved a signiﬁcant higher number of liver biop-
sies than the single non-invasive markers (P < 0.0001).
Fibropaca algorithm showed a signiﬁcantly higher accu-
Table 1 | Demographic, laboratory and histological
features of 1013 HCV patients
Gender (%)
Males 574 (56.7%)
Females 439 (43.3%)
Age (mean years  SD) 48.0  12.0
BMI (mean Kg ⁄m2  SD) 24.6  3.7
AST (mean IU ⁄ L  SD) 70  66
AST ⁄ULN ratio (mean  SD) 1.56  1.47
ALT (mean IU ⁄ L  SD) 102  99
ALT ⁄ULN ratio (mean  SD) 2.27  2.2
cGT (mean IU ⁄ L  SD) 72.4  107.1
cGT ⁄ULN ratio (mean  SD) 1.31  1.95
Platelet count (mean 109 ⁄ L  SD) 208.6  19.4
Cholesterol levels (mean mmol ⁄ L  SD) 2.5  1.4
HCV Genotype (%)
HCV-1 655 (64.7)
HCV-2 112 (11.1)
HCV-3 153 (15.1)
HCV-4 71 (7.0)
HCV-5 18 (1.8)
HCV-6 4 (0.3)
Liver Fibrosis according to METAVIR (%)
F0 105 (10.4)
F1 356 (35.1)
F2 294 (29)
F3 145 (14.3)
F4 113 (11.2)
HCV, hepatitis C virus; SD, standard deviation; BMI, body mass
index; AST, aspartate aminotransferase; ALT, alanine amino-
transferase; cGT, c-glutamyl-transpeptidase; ULN, upper limits
of normal.
Combination algorithms for liver fibrosis in HCV
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racy than the single non-invasive markers (P < 0.0001).
Moreover, it saved a signiﬁcant higher number of liver
biopsies than the single non-invasive markers
(P < 0.0001). Leroy algorithm showed a signiﬁcantly
higher accuracy than the single non-invasive markers
(P < 0.0001). However, it saved a number of liver biop-
sies that was signiﬁcantly inferior to that of Fibrotest
alone (29.2% vs. 34.8%, P = 0.008) and superior only to
APRI (29.2% vs. 15.6%, P < 0.0001). Overall, SAFE
biopsy showed an AdjAUROC of 0.96% and 90.3% accu-
racy. Liver biopsy could have been saved in 444 (43.8%)
patients (Figure 1). Fibropaca algorithm showed an Ad-
jAUROC of 0.94% and 87.6% accuracy. Liver biopsy
could have been saved in 524 (51.7%) patients (Figure 3).
Leroy algorithm showed an AdjAUROC of 1 and 93.5%
accuracy. Liver biopsy could have been saved in 296
(29.2%) patients (Figure 5). The number of saved liver
biopsies was signiﬁcantly higher using Fibropaca algo-
rithm than SAFE biopsy (P = 0.0003). Conversely, the
accuracy of SAFE biopsy was signiﬁcantly higher than
that of Fibropaca algorithm (P = 0.05). Leroy algorithm
showed a signiﬁcantly higher accuracy when compared
to SAFE biopsy and Fibropaca algorithm (P = 0.009 and
P < 0.0001, respectively). However, it saved signiﬁcantly
less liver biopsies as compared with SAFE biopsy and
Fibropaca algorithm (P < 0.0001).
Combination algorithms for diagnosis of cirrhosis
The performance of the two algorithms able to diagnose
liver cirrhosis is described in Table 3. Figures 2 and 4
describe the SAFE biopsy and Fibropaca algorithm for cir-
rhosis, respectively, including related decisional tree and
distribution of the study population. SAFE biopsy showed
a signiﬁcantly higher accuracy than the single non-inva-
sive markers (P < 0.0001). Moreover, it saved a signiﬁcant
higher number of liver biopsies than the single non-inva-
sive markers (P < 0.0001). Fibropaca algorithm showed a
signiﬁcantly higher accuracy than the single non-invasive
markers (P < 0.0001). Moreover, it saved a signiﬁcant
higher number of liver biopsies than the single non-inva-
sive markers (P < 0.0001). Overall, SAFE biopsy showed
an AdjAUROC of 0.93% and 91.2% accuracy. Liver biopsy
could have been saved in 801 (79.1%) patients (Figure 2).
Fibropaca algorithm showed an AdjAUROC of 0.91% and
94.0% accuracy. Liver biopsy could have been saved in 772
(76.2%) patients (Figure 4). The number of saved liver
Table 2 | Performance of the
three algorithms for diagnos-
ing significant fibrosis (‡F2 by
METAVIR) in 1013 HCV
patients
SAFE biopsy Fibropaca algorithm Leroy algorithm
Fibrotest
(% of tests needed)
43.2 100 100
APRI
(% of tests needed)
100 100 100
Forns’ index
(% of tests needed)
0 100 0
Accuracy (%) 90.3 87.6 93.5
Sensitivity (%) 100 85.5 89.6
Specificity (%) 78.2 89.9 97.8
PPV (%) 83.7 90.5 89.6
NPV (%) 100 84.7 97.8
LR+ 4.59 8.47 40.72
LR) 0 0.16 0.1
ObAUROC (95% CI) 0.90
(0.85–0.95)
0.88
(0.82–0.94)
0.94
(0.89–0.99)
DANA 1.9 1.9 1.9
AdjAUROC (95% CI) 0.96
(0.91–1)
0.94
(0.88–1)
1 (0.95–1)
Saved liver biopsies (%) 43.8 51.7 29.2
HCV, hepatitis C virus; SAFE, sequential algorithm for fibrosis evaluation; APRI, AST-to-
platelet ratio index; PPV, positive predictive value; NPV, negative predictive value; LR,
likelihood ratio; ObAUROC, observed area under the receiver operating characteristic
curve; DANA, difference between advanced and non-advanced fibrosis; AdjAUROC,
adjusted area under the receiver operating characteristic curve; CI, confidence interval.
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biopsies did not differ between SAFE biopsy and Fibro-
paca algorithm (P = 0.12). Accuracy of Fibropaca algo-
rithm was signiﬁcantly higher than that of SAFE biopsy
(P = 0.02).
Influence of liver biopsy length
To assess if and how the characteristics of liver specimens
affect the concordance between Fibrotest and liver biopsy,
the performance of those cases with ‘gold’ standard liver
biopsy was investigated separately and compared with the
whole population of patients. Performance of the three
algorithms was not signiﬁcantly inﬂuenced by the length
of liver biopsy (data not shown).
Combination algorithms in HCV elderly patients
To assess the performance of the combination algorithms
in patients who may have a peculiar distribution of liver
ﬁbrosis stages, a dedicated analysis was performed on
HCV elderly patients (age ‡ 65 years), who are expected
to have a higher prevalence of advanced ﬁbrosis stages.
These patients represent a signiﬁcant proportion of HCV
carriers in the general population in most Western
Countries. Moreover, the indication to perform a liver
biopsy in these cases is often debated and controver-
sial.35, 36
Overall, 91 (9.0%) cases were over 65 years of age,
including 33 (36.3%) men and 58 (63.7%) women, with
mean age of 69.6  4.0 years. Signiﬁcant ﬁbrosis was
present in 63 (69.2%) patients while cirrhosis was pres-
ent in 14 (15.4%). Prevalence of signiﬁcant ﬁbrosis was
signiﬁcantly higher in the elderly patients than in the
whole study population (signiﬁcant ﬁbrosis being present
in 69.2% vs. 54.5%, P = 0.006). No signiﬁcant difference
was observed in the prevalence of cirrhosis between
HCV elderly patients and the whole study population
(15.4% vs. 11.2%, P = 0.22). The performance of the
combination algorithms for signiﬁcant ﬁbrosis in HCV
elderly patients was as follows: SAFE biopsy (AdjAU-
ROC = 0.97, accuracy = 94.5%, PPV = 92.6%, NPV =
100%); Fibropaca algorithm (AdjAUROC = 0.95, accu-
racy = 91.5%, PPV = 93.5%, NPV = 82.2%); Leroy algo-
rithm (AdjAUROC = 1, accuracy = 96.7%, PPV = 98.4%,
NPV = 93.1%). For the diagnosis of signiﬁcant ﬁbrosis,
liver biopsy could have been saved in 37 (59.3%) patients
with SAFE biopsy, 51 (56%) patients with Fibropaca
algorithm and 35 (38.5%) patients with Leroy algorithm.
The performance of the combination algorithms for cir-
rhosis in HCV elderly patients was as follows: SAFE
biopsy (AdjAUROC = 0.95, accuracy = 93.0%, PPV =
65.1%, NPV = 95.9%); Fibropaca algorithm (AdjAU-
ROC = 0.98, accuracy = 91.2%, PPV = 65.0%, NPV =
93.2%). For the diagnosis of cirrhosis, liver biopsy could
have been saved in 73 (80.2%) patients with SAFE biopsy
and 57 (62.6%) with Fibropaca algorithm.
Even though there was a tendency for a higher perfor-
mance of all the combination algorithms in the HCV
elderly patients, especially for the diagnosis of signiﬁcant
ﬁbrosis, the difference with respect to the whole study
population was not statistically signiﬁcant.
Other variables influencing the performance of the
three algorithms
The performance of the three combination algorithms in
relation to several demographic and serological variables
was investigated. Gender, BMI, levels of transaminases,
HCV genotype did not show any signiﬁcant inﬂuence on
the performance of the three algorithms for both signiﬁ-
Table 3 | Performance of SAFE biopsy and Fibropaca
algorithm for diagnosing cirrhosis (F4 by METAVIR) in
1013 HCV patients
SAFE biopsy Fibropaca algorithm
Fibrotest
(% of tests needed)
57.6 100
APRI
(% of tests needed)
100 100
Forns’ index
(% of tests needed)
NA NA
Accuracy (%) 91.2 94.0
Sensitivity (%) 81.8 72.7
Specificity (%) 92.4 96.7
PPV (%) 57.4 73.4
NPV (%) 97.6 95.6
LR+ 10.76 22.0
LR) 0.2 0.28
ObAUROC (95% CI) 0.87
(0.81–0.93)
0.85
(0.79–0.91)
DANA 1.9 1.9
AdjAUROC (95% CI) 0.93
(0.87–0.99)
0.91
(0.85–0.97)
Saved liver
biopsies (%)
79.1 76.2
HCV, hepatitis C virus; SAFE, sequential algorithm for fibrosis
evaluation; APRI, AST-to-platelet ratio index; PPV, Positive Pre-
dictive Value; NPV, negative predictive value; LR, likelihood
ratio; ObAUROC, observed area under the receiver operating
characteristic curve; DANA, difference between advanced and
non-advanced fibrosis; AdjAUROC, adjusted area under the
receiver operating characteristic curve; CI, confidence interval.
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cant ﬁbrosis and cirrhosis, even when corrected for
DANA. Moreover, the inter-centre variability was mar-
ginal (data not shown).
Analysis of discordant cases
Analysis of discordant cases between the combination
algorithms and liver biopsy is shown in Table S3. For
the diagnosis of signiﬁcant ﬁbrosis, discordance due to
biopsy was observed in 32.7%, 21.4% and 34.8% with
SAFE biopsy, Fibropaca algorithm and Leroy algorithm,
respectively; discordance due to non-invasive markers
was observed in 44.9%, 45.2% and 45.5% with SAFE
biopsy, Fibropaca algorithm and Leroy algorithm, respec-
tively. The rest of discordant cases were undetermined.
For the diagnosis of cirrhosis, discordance due to biopsy
was observed in 47.2% and 42.6% with SAFE biopsy and
Fibropaca algorithm respectively; discordance due to
non-invasive markers was observed in 33.7% and 36.0%
with SAFE biopsy and Fibropaca algorithm respectively.
The rest of discordant cases were undetermined.
Cost–benefit analysis
For the purpose of the cost–beneﬁt analysis, we esti-
mated the cost of an uncomplicated liver biopsy to be
700 Euros and the cost of a Fibrotest to be 100 Euros,
while no extra costs were considered for APRI and
Forns’ index, as patients with CHC usually undergo rou-
tinely the needed blood tests during their follow-up. On
the same line, the price of total bilirubin and cGT, that
are routinely performed, was not considered for
Fibrotest. It should also be mentioned that Actitest, a
non-invasive test that gives an estimation of the necroin-
ﬂammatory activity in the liver, is calculated as free with
Fibrotest.37 In this analysis, performing liver biopsy in all
1013 patients with CHC would cost 709 100 Euros for
diagnosis of signiﬁcant ﬁbrosis (‘universal biopsy strat-
egy’) (Table 4). The cost of ‘Fibrotest strategy’, ‘APRI
strategy’, ‘SAFE biopsy strategy’, ‘Fibropaca algorithm
strategy’ and ‘Leroy strategy’ would be 565 400 Euros,
598 00 Euros, 442 100 Euros, 443 600 Euros and
603 200 Euros, respectively. Thus, there would be a rele-
Table 4 | Cost–benefit analysis of the ‘universal biopsy strategy’ vs. ‘single non-invasive markers’ and ‘combination
algorithms strategy’ for the diagnosis of significant fibrosis (‡F2 by METAVIR) as for 1013 HCV patients
Universal
biopsy
strategy
Fibrotest
strategy
APRI
strategy
SAFE biopsy
strategy
Fibropaca
algorithm
strategy
Leroy
algorithm
strategy
Cost of liver biopsy (Euros) 709 100 464 100 598 500 398 300 342 300 501 900
Cost of Fibrotest (Euros) 0 101 300 0 43 800 101 300 101 300
Total cost (Euros) 709 100 565 400 598 500 442 100 443 600 603 200
Saved cost vs. biopsy strategy (Euros) – 143 700 110 600 267 000 265 500 105 900
Misclassified cases (n) – 145 102 98 126 66
HCV, hepatitis C virus; APRI, AST-to-platelet ratio index; SAFE, sequential algorithm for fibrosis evaluation.
Table 5 | Cost–benefit analysis of the ‘universal biopsy strategy’ vs. ‘single non-invasive markers’ and ‘combination
algorithms strategy’ for the diagnosis of cirrhosis (F4 by METAVIR) in 1013 HCV patients
Universal
biopsy
strategy
Fibrotest
strategy
APRI
strategy
SAFE
biopsy
strategy
Fibropaca
algorithm
strategy
Cost of liver biopsy (Euros) 709 100 240 100 303 100 148 400 168 700
Cost of Fibrotest (Euros) 0 101 300 0 58 300 101 300
Total cost (Euros) 709 100 341 400 303 100 206 700 270 000
Saved cost vs. biopsy strategy (Euros) – 367 700 406 000 502 400 439 100
Misclassified cases (n) – 93 40 89 61
HCV, hepatitis C virus; APRI, AST-to-platelet ratio index; SAFE, sequential algorithm for fibrosis evaluation.
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vant reduction in the screening costs, especially with
‘SAFE biopsy strategy’ and ‘Fibropaca algorithm strategy’.
Regarding the diagnosis of cirrhosis, performing liver
biopsy in all patients with CHC would cost 709 100
Euros (‘universal biopsy strategy’) (Table 5). The cost
of ‘Fibrotest strategy’, ‘APRI strategy’, ‘SAFE biopsy strat-
egy’ and ‘Fibropaca algorithm strategy’ would be 341 400
Euros, 303 100 Euros, 206 700 Euros and 270 000 Euros
respectively. Thus, there would be a relevant reduction in
the screening costs, especially with ‘SAFE biopsy strategy’
and ‘Fibropaca algorithm strategy’.
DISCUSSION
This study, based on a large consecutive population of
patients with CHC, suggests that, among a number of
combination algorithms using serum non-invasive mark-
ers for liver ﬁbrosis, SAFE biopsy and Fibropaca algo-
rithm may save up to 79% liver biopsies by preserving
an excellent accuracy, thus leading to a signiﬁcant reduc-
tion in the screening costs. Moreover, SAFE biopsy and
Fibropaca algorithm showed a signiﬁcantly higher per-
formance and saved a signiﬁcantly higher number of
liver biopsies as compared with the single non-invasive
methods adopted. This represents the ﬁrst large-scale
study, which compares three algorithms combining the
most validated serum non-invasive markers for liver
ﬁbrosis in CHC, that are Fibrotest, APRI and Forns’
index.
Staging of liver ﬁbrosis has always been considered of
paramount importance for the deﬁnition of prognosis
and urgency for antiviral treatment in patients with
CHC.2 However, considering the huge number of HCV
carriers worldwide, it is inconceivable to take a liver
biopsy in all of them due to its cost and invasiveness.
Indeed, a signiﬁcant number of patients may refuse liver
biopsy and the hepatologists themselves may have con-
cerns about how to use it in clinical practice.9, 10
Although numerous serum non-invasive markers for
liver ﬁbrosis have been developed in the last decade,
their implementation in clinical practice remains still
limited by the scepticism shared by many clinicians on
their diagnostic accuracy in substitution of liver histol-
ogy.12 Indeed, in patients with CHC, the diagnostic accu-
racy of these markers does not overcome 75–85% when
used individually, these values being in the lower range
particularly for identiﬁcation of signiﬁcant ﬁbrosis.17
More recently, it has been proposed that combinations
of serum non-invasive markers may allow for reaching
higher diagnostic accuracy.13, 17, 24, 38 The rationale for
using such combinations of serum non-invasive markers
is to reduce, rather than abolish, the need for liver biop-
sies. In this view, combinations of complementary serum
non-invasive markers has been proposed as the initial
step for disease staging, limiting liver biopsy to those
cases in which the diagnostic accuracy of non-invasive
markers appears unsatisfactory.
Recently, the Asian Paciﬁc Association for the Study
of the Liver has produced guidelines about liver ﬁbrosis
management. The guidelines concluded that a stepwise
algorithm incorporating non-invasive markers of ﬁbrosis
may reduce the number of liver biopsies by about 30%.25
In the present study, we compared three algorithms that
combine the most validated serum non-invasive markers
for liver ﬁbrosis in a large population of patients with
CHC, using liver biopsy as the standard of reference. It
should be noted that liver biopsy remains an imperfect
gold standard due to intra- and inter-observer variability,
which mainly depends on the quality of liver specimen.4–
7 Interestingly, the group that patented Fibrotest has sug-
gested that Fibrotest and biopsy may have a similar
prognostic value and a similar risk of false positiv-
ity ⁄negativity.39 Moreover, few reports indicate that
serum ﬁbrosis markers may be associated with portal
hypertension, liver disease progression and the outcome
of liver disease.40–42
Nevertheless, as liver biopsy remains the only direct
way to assess liver histology, guidelines still recommend
it for the staging of hepatic ﬁbrosis.2 Indeed, the Ameri-
can Association for the Study of Liver Diseases has
recently produced a position paper about liver biopsy,
recommending a sample of at least 20 mm in length and
containing at least 11 complete portal tracts. Moreover,
in clinical practice, it was recommended the use of a
simple (METAVIR) rather than complex (Ishak) scoring
system for liver ﬁbrosis.3 In our large-scale study, liver
histological assessment was performed according to
METAVIR system as recommended. On the other hand,
liver biopsy samples were somehow suboptimal, around
half of the specimens being longer than 20 mm. How-
ever, a subgroup analysis aimed to investigate the perfor-
mance of the three algorithms only in those patients
with a ‘gold’ standard liver biopsy did not show any sig-
niﬁcant difference with respect to the overall population
studied. This is consistent with other reports suggesting
that performance of Fibrotest does not depend on the
size of liver specimen.43, 44 The lack of evaluation by a
single Pathologist of all biopsies could be seen as a weak-
ness of our study, but it better reﬂects what occurs in
real life. Furthermore, the diagnostic performance of the
three algorithms remained unchanged compared with
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the whole cohort when only patients having liver biopsy
evaluated by a single Pathologist were considered (data
not shown).
The overall accuracy for detection of signiﬁcant ﬁbrosis
was very good for SAFE biopsy, Fibropaca algorithm and
Leroy algorithm. However, Leroy algorithm saved much
less liver biopsies than the other two algorithms and than
Fibrotest alone (only 29.2%). SAFE biopsy had a slightly
better performance with respect to Fibropaca algorithm.
However, Fibropaca algorithm saved more liver biopsies.
For diagnosis of cirrhosis, Fibropaca algorithm showed a
signiﬁcantly better performance than SAFE biopsy. The
results of our study are consistent with the original studies
in which the algorithms were proposed.21–23 SAFE biopsy
has also been validated in a large-scale international study
including more than 2000 patients with CHC. This study
represents the largest independent study on serum non-
invasive markers for liver ﬁbrosis.26
Thanks to the large number of patients included in
the study, we were also able to perform a subgroup anal-
ysis aimed to assess the performance of combination
algorithms in HCV elderly patients, who may have a
peculiar distribution of liver ﬁbrosis stages. In these
patients, liver biopsy is even more questionable.35, 36
Indeed, in elderly HCV patients, the greater prevalence
of liver disease is linked to higher morbidity and mortal-
ity, which are excellent reasons for improving the evalua-
tion of liver ﬁbrosis and for a better identiﬁcation of
indication to antiviral therapies.35, 36 It has been sug-
gested that the prevalence of advanced ﬁbrosis and cir-
rhosis in the study population may signiﬁcantly affect
the performance of non-invasive markers in terms of
PPV and NPV.45 In the present study, even though there
was a tendency for higher accuracies and PPVs, and
slightly inferior NPVs in HCV elderly patients as com-
pared with the whole study population, these differences
were not statistically signiﬁcant. This is likely because in
this population of patients, the prevalence of elderly
patients was relatively limited (91 cases with age ‡ 65 -
years) and the prevalence of cirrhosis in this subgroup
was not signiﬁcantly higher than in the whole population
study (15.4% vs. 11.2%). We can interpret this fact by
considering that the study was retrospective and most of
the patients underwent both liver biopsy and non-inva-
sive markers as they were candidate for antiviral therapy.
Other studies have reported that combination algo-
rithms of serum non-invasive markers may increase the
performance of the single tests. An algorithm combining
synchronously Fibrotest and Fibroscan has also been
proposed and we have recently compared it with SAFE
biopsy in a prospective study of 302 patients with CHC,
concluding that both algorithms are effective for assess-
ment of liver ﬁbrosis in CHC.46 An algorithm combining
Hepascore, a patented test, and APRI was recently pro-
posed.30, 47 The authors reported a high diagnostic accu-
racy (91%) with 45% saved liver biopsies to diagnose
signiﬁcant ﬁbrosis. However, the main limitation of this
algorithm is that Hepascore is not as validated as APRI,
Fibrotest and Forns’ index. On the same line, Cales and
colleagues reported that a combination of Fibrometer, a
patented test, and Fibrotest may save 44.8% liver biopsies
with an overall accuracy of 95.3%.48 On the basis of their
study, Cales and colleagues have suggested that synchro-
nous combination algorithms may be more effective than
sequential algorithms such as SAFE biopsy. However,
although Fibrometer had a good performance in studies
coming from the patenting group, it has been validated
less than Fibrotest and APRI.49, 50 Moreover, Fibrometer
is not licensed in as many countries as Fibrotest.
Our study has several limitations. First, as already
mentioned, this was a retrospective study. Second, most
of the algorithms proposed here did not reach 100% pre-
dictive values, except for SAFE biopsy for signiﬁcant
ﬁbrosis, therefore the cost of false positive (i.e. the cost of
having unnecessary surveillance ⁄ investigations) and the
cost of false negatives (i.e. the cost of missing ﬁbrosis ⁄ cir-
rhosis) should be considered. The misclassiﬁed cases were
mostly false positives. We might speculate that, for signif-
icant ﬁbrosis, false positives would undergo an antiviral
therapy that they would most likely need anyway in a
short time and, for cirrhosis, false positives would start a
surveillance programme that is not completely inappro-
priate as most of them had severe liver ﬁbrosis (F3 and
F3–F4 by METAVIR). An analysis of discordant cases
between the combination algorithms and liver biopsy for
signiﬁcant ﬁbrosis and cirrhosis was also carried out.
Overall, when considering liver biopsies of poor quality,
between one-third and 45% of the discordances could be
highly attributable to liver biopsy failure.
Third, no information about fragmentation of liver
biopsy specimens was available. Indeed, it has been dem-
onstrated that the number of fragments may have a sig-
niﬁcant impact on the AUROC of non-invasive
markers.51
Fourth, potential limitations of the use of predictive
values for decision making due to their reliance on prev-
alence should be acknowledged. Nevertheless, most perti-
nent studies published to date have used predictive
values.13–16, 23, 52 The relevance of the prevalence of
ﬁbrosis stages on the performance of non-invasive mark-
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ers is here underscored by the correction of AUROCs by
DANA.
In conclusion, based on the results of this multicentre,
large-scale study, SAFE biopsy and Fibropaca algorithms
are attractive methods in clinical practice for large-scale
screening of liver ﬁbrosis in hepatitis C. These algorithms
may be particularly useful to screen HCV-infected indi-
viduals, where an immediate approach with liver biopsy
is particularly problematic or questionable, such as elderly
HCV carriers. The algorithm for signiﬁcant ﬁbrosis may
be particularly indicated to screen HCV patients for indi-
cation to initiate antiviral therapy, while the algorithm for
cirrhosis may be ideal for the follow-up of patients
already known to have progressed to signiﬁcant ﬁbrosis
based on previous histological evaluation.
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